A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. - Rustin, G.; Vergote, I.; Micha, J.P.; Duska, L.R.; Reed, N.; Bendell, J.; Spitz, D.; Dark, G.; Hoch, U.; Tagliaferri, M.; Hannah, A.L.; Garcia, A.A. (Gynecologic Oncology, 2017)